Inflarx N.V. (IFRX)
NASDAQ:IFRX
Want to see IFRX full AI Analyst Report?
Top Page
InflaRx
(NASDAQ:IFRX)
Select Model
Select Model
Rating:53Neutral
Price Target:
$2.50
▲(57.23% Upside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by weak financial performance (negligible revenue, persistent losses, and ongoing cash burn despite low leverage). Strong technical momentum (price above key moving averages with positive MACD) supports the score, but the setup looks extended (high RSI/Stoch). Valuation remains challenged due to a negative P/E and no dividend support.
Positive Factors
Extended funding runway
Management shifted focus to izicopan and reports cash + strategic actions that are expected to fund planned izicopan programs, key PoC and Phase 2 readouts, and operations through 2029. This materially reduces near-term financing pressure and supports multi-year program execution.
Negative Factors
Sustained cash burn
Operating and free cash flow remain materially negative and closely track net losses, indicating real cash consumption rather than non‑cash accounting charges. Over time this necessitates frequent capital raises or partnerships, creating execution risk if clinical milestones slip or financing windows tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended funding runway
Management shifted focus to izicopan and reports cash + strategic actions that are expected to fund planned izicopan programs, key PoC and Phase 2 readouts, and operations through 2029. This materially reduces near-term financing pressure and supports multi-year program execution.
Read all positive factors
InflaRx (IFRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$188.68M
Dividend YieldN/A
Average Volume (3M)2.83M
Price to Earnings (P/E)―
Beta (1Y)1.58
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees74
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.61
Shares Outstanding72,292,860
10 Day Avg. Volume1,940,570
30 Day Avg. Volume2,834,089
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.39
Price to Sales (P/S)1972.04
P/FCF Ratio-1.70
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue5.06K
Enterprise Value/Gross Profit-20.53
Enterprise Value/Ebitda-3.50
Forecast
1Y Price Target
$8.00Price Target Upside403.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$13.29K
InflaRx Business Overview & Revenue Model
Company Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a var...
How the Company Makes Money
InflaRx is a clinical-stage company and, based on publicly available information, it has not established a broad, recurring revenue base from marketed products. Its potential and/or historical sources of cash and revenue typically include: (1) col...
InflaRx Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.33K | 29.33K | 165.79K | 63.09K | 0.00 | 0.00 |
| Gross Profit | -7.23M | -7.24M | -3.15M | -469.17K | 0.00 | 0.00 |
| EBITDA | -42.36M | -45.16M | -45.55M | -42.06M | -28.84M | -44.94M |
| Net Income | -42.91M | -45.63M | -46.06M | -42.67M | -29.48M | -45.63M |
Balance Sheet | ||||||
| Total Assets | 48.94M | 55.19M | 76.02M | 120.21M | 102.40M | 125.14M |
| Cash, Cash Equivalents and Short-Term Investments | 39.84M | 46.44M | 18.38M | 12.77M | 81.81M | 83.41M |
| Total Debt | 823.88K | 897.53K | 805.09K | 1.12M | 1.36M | 1.43M |
| Total Liabilities | 12.01M | 13.65M | 14.60M | 17.63M | 14.05M | 19.86M |
| Stockholders Equity | 36.93M | 41.54M | 61.42M | 102.58M | 88.35M | 105.28M |
Cash Flow | ||||||
| Free Cash Flow | -28.93M | -34.03M | -48.60M | -37.89M | -33.91M | -39.97M |
| Operating Cash Flow | -28.81M | -33.92M | -48.56M | -37.81M | -33.74M | -39.94M |
| Investing Cash Flow | -8.18M | 3.11M | 52.36M | -17.70M | 19.36M | -25.95M |
| Financing Cash Flow | 6.23M | 32.00M | 386.45K | 52.99M | 1.94M | 61.58M |
InflaRx Technical Analysis
Positive
1.59
Price Trends
1.58
Positive
1.27
Positive
1.25
Positive
Market Momentum
0.27
Positive
68.75
Neutral
54.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Positive. The current price of 1.59 is below the 20-day moving average (MA) of 2.30, above the 50-day MA of 1.58, and above the 200-day MA of 1.25, indicating a bullish trend. The MACD of 0.27 indicates Positive momentum. The RSI at 68.75 is Neutral, neither overbought nor oversold. The STOCH value of 54.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IFRX.
InflaRx Risk Analysis
InflaRx disclosed 82 risk factors in its most recent earnings report. InflaRx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
InflaRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $163.30M | 0.90 | 60.96% | ― | -100.00% | ― | |
53 Neutral | $188.68M | -2.50 | -91.12% | ― | ― | ― | |
52 Neutral | $85.61M | -1.77 | 233.93% | ― | -61.71% | -11.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $88.30M | -4.02 | 25.68% | ― | -88.41% | 76.14% | |
| ― | $93.54M | -9.85 | -65.55% | ― | ― | 19.02% | |
47 Neutral | $181.29M | -1.80 | -123.07% | ― | ― | 3.91% |
* Healthcare Sector Average
IFRX
InflaRx
2.61
0.76
41.08%
ORMP
Oramed Pharm
3.99
2.01
101.92%
ATRA
Atara Biotherapeutics
9.80
2.31
30.84%
ANIX
Anixa Biosciences
2.79
0.29
11.60%
CLNN
Clene
6.70
4.33
182.70%
ABOS
Acumen Pharmaceuticals
2.51
1.49
146.08%
InflaRx Corporate Events
InflaRx Raises $150 Million in Underwritten Share Offering Filed in Early May 2026
May 7, 2026
On May 6, 2026, InflaRx N.V. signed an underwriting agreement with Guggenheim Securities for an underwritten public offering of 75 million ordinary shares at $2.00 per share, which closed on May 7, 2026. The transaction, conducted under the compan...
InflaRx Refocuses Izicopan on Vasculitis and Renal Diseases With Funding Runway to 2029
May 6, 2026
On May 6, 2026, InflaRx announced a strategic focus on developing its oral C5a receptor inhibitor izicopan for ANCA-associated vasculitis, a life-threatening kidney disorder, with Phase 2 planning under way and multiple development paths being eva...
InflaRx Files Q1 2026 Financials with SEC via Form 6-K
May 6, 2026
InflaRx N.V. has filed a Form 6-K with the U.S. Securities and Exchange Commission for May 2026, incorporating its latest unaudited condensed consolidated financial statements and management’s discussion and analysis for the quarter ended Ma...
InflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical Study
May 4, 2026
On May 4, 2026, InflaRx reported new preclinical data showing that its investigational C5aR1 inhibitor izicopan generates minimal reactive metabolites in human liver microsomes, suggesting a low level of bioactivation in this in vitro assay. React...
InflaRx Regains Nasdaq Minimum Bid Price Compliance, Securing Listing Status
Apr 28, 2026
InflaRx N.V., a Nasdaq-listed biopharmaceutical group based in Germany and the U.S., focuses on anti-inflammatory drugs that inhibit the complement activation factor C5a and its receptor, C5aR. Its lead candidate is izicopan, an oral C5a receptor ...
InflaRx Shareholders Approve Capital, Governance Changes and 2026 Incentive Plan at April AGM
Apr 23, 2026
On April 23, 2026, InflaRx held its annual general meeting of shareholders, where investors approved the Dutch statutory annual accounts for the year ended December 31, 2025, and reappointed KPMG Accountants N.V. as external auditor for 2026. Shar...
InflaRx Highlights New Izicopan Data Showing No CYP3A4 Time-Dependent Inhibition
Apr 9, 2026
On April 9, 2026, InflaRx reported new in vitro mechanistic data showing that its lead candidate izicopan does not exhibit time-dependent inhibition of CYP3A4, a key enzyme involved in metabolizing many drugs and a common source of drug–drug...
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP
Apr 2, 2026
On April 2, 2026, InflaRx N.V. announced it had convened its 2026 annual general meeting of shareholders for April 23, 2026 in Amsterdam, setting March 26, 2026 as the record date and outlining attendance and proxy procedures for registered and be...
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027
Mar 19, 2026
On March 19, 2026, InflaRx reported its full-year 2025 results and outlined a strategic pivot to focus on izicopan after promising Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria, with Phase 2b planning in HS underway a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.